Skip to main content
. 2015 May 28;4(6):e001833. doi: 10.1161/JAHA.115.001833

Figure 2.

Figure 2

Combined RRs (95% CI) for cardiovascular outcomes in individuals in the top compared with those in the bottom third of ADMA and SDMA concentration. When analysis was restricted to studies that reported on both methylarginines (for direct comparison), the RR of ADMA was 1.40 (1.16, 1.68) for CVD, 1.24 (1.01, 1.52) for CHD, and 1.57 (1.12, 2.20) for stroke and the RR of SDMA was 1.32 (0.92, 1.90) for CVD, 1.44 (0.77, 2.67) for CHD, and 1.31 (0.83, 2.07) for stroke. ADMA indicates asymmetric dimethylarginine; CHD, coronary heart disease; CVD, cardiovascular disease; RR, risk ratio; SDMA, symmetric dimethylarginine.